PRME - NASDAQ
Prime Medicine, Inc.
$3.14
-2.2%Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotPrime Medicine, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Prime Medicine, Inc. Cash Flow Statement
PRME • NASDAQ
| Prime Medicine, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-201.1M | -195.9M | -198.1M | -121.8M | -165.4M | -3.4M | -2.5M | |
5.4M | 6.1M | 4.7M | 2.2M | 568K | 43K | 0.0 | |
0.0 | 0.0 | -279K | -964K | -624K | 1.9M | 0.0 | |
29.3M | 26.1M | 13.9M | 6.5M | 1.7M | 391K | 0.0 | |
9.3M | 9.7M | 11.8M | 17.7M | 98.4M | -4.6M | 703K | |
(0.0) | (0.0) | (0.0) | (141K) | (0.0) | (0.0) | (0.0) | |
-5.3M | 31.1M | 2.6M | -35.4M | 31.2M | 164K | 492K | |
-162.6M | -122.9M | -165.4M | -131.8M | -34.1M | -5.5M | -1.3M | |
INVESTING ACTIVITIES | |||||||
-4.5M | -7.3M | -8.7M | -16.1M | -4.2M | -639K | (0.0) | |
-205.4M | -129.4M | -105M | -123.3M | -82M | (0.0) | (0.0) | |
101.2M | 204.2M | 132.6M | 93M | 13M | 0.0 | 0.0 | |
0.0 | 1M | -170K | -665K | -496K | -423K | 0.0 | |
-108.8M | (68.5M) | (18.7M) | -47.1M | -73.6M | -1.1M | (0.0) | |
FINANCING ACTIVITIES | |||||||
139.5M | 170.1M | 655K | 185.3M | 0.0 | 0.0 | 0.0 | |
12M | 25.7M | 0.0 | -3.8M | -1.1M | -20K | 10M | |
151.5M | 195.9M | 655K | 181.5M | 269.3M | 34.9M | 10M | |
CASH FLOW SUMMARY | |||||||
-119.8M | 141.5M | -146M | 2.6M | 161.6M | 28.3M | 8.6M | |
196.5M | 55.1M | 201.1M | 198.5M | 37M | 8.6M | 0.0 | |
76.7M | 196.5M | 55.1M | 201.1M | 198.5M | 37M | 8.6M | |
-167.1M | -130.2M | -174.1M | -147.9M | -38.2M | -6.2M | -1.3M |
SEC Filings
PRME - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 07, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 07, 2025 | November 07, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 07, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 08, 2025 | September 08, 2025 | 2025 |
Related Guides
Continue your PRME research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.